



Please Note: Medical Necessity Prior Authorization may be overridden for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

## PRIOR AUTHORIZATION **BYPASS**

### **Granix® (tbo-filgrastim)**

Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Name \_\_\_\_\_  
 Address \_\_\_\_\_

**Rx**

as directed by physician

MD \_\_\_\_\_  
 Signature \_\_\_\_\_

Name \_\_\_\_\_  
 Address \_\_\_\_\_

**Rx COMPLETE PRIOR AUTHORIZATION FORMS**

Dx: BONE MARROW SUPPRESSION  
 ICD 10: D 70.1

MD \_\_\_\_\_  
 Signature \_\_\_\_\_

# SAMPLE



**Prescriber Information**

<b>Last Name:</b> <input type="text"/> <b>DEA/NPI:</b> <input type="text"/> <b>Phone</b> <input type="text"/>	<b>First Name</b> <input type="text"/> <b>Specialty:</b> <input type="text"/> <b>Fax</b> <input type="text"/>
--	--

**Member Information**

<b>Last Name:</b> <input type="text"/> <b>Member ID Number</b> <input type="text"/>	<b>First Name</b> <input type="text"/> <b>DOB:</b> <input type="text"/>
--	--

**Medication Information:**

<b>Drug Name and Strength:</b> <hr/> <b>Diagnosis:</b> <hr/>	<b>Quantity and Dosing:</b> <hr/> <b>Duration:</b> <hr/>
--	--

When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process.

**Neupogen & Leukine Prior Authorization Form**

**You must answer ALL of the following questions**

1. Is the patient 18 years of age or older?	Y	N
2. Has the patient had a trial and failure of Granix?	Y	N
<i>Please provide documentation.</i>		
3. Is the prescribed medication being used to prevent febrile neutropenia in a previously untreated adult or pediatric patient?	Y	N
4. Does the patient have a diagnosis of a non-myeloid malignancy and is the patient receiving chemotherapy and/or radiotherapy with an expected incidence of febrile neutropenia of 20% or greater?	Y	N
5. Is the patient at an increased risk for developing chemotherapy-induced infections due to any of the following reasons? <b>(Please Circle)</b>	Y	N
<ul style="list-style-type: none"> <li>• Pre-existing neutropenia (ANC of 1,000/mm<sup>3</sup> or less)</li> <li>• Extensive prior exposure to chemotherapy</li> <li>• Previous exposure of pelvis or other areas of large amounts of bone marrow to radiation</li> <li>• History of recurrent febrile neutropenia from chemotherapy</li> <li>• Patient is 65 years of age or older</li> <li>• Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS)</li> </ul>		
<i>Please submit documentation.</i>		



6. Does the patient have any of the following conditions? <b>(Please Circle)</b>	Y	N
<ul style="list-style-type: none"> <li>ANC of 1,000/mm<sup>3</sup> or less with BMT or myelodysplasia related neutropenia</li> <li>ANC of 500/mm<sup>3</sup> or less with HIV/AIDS</li> <li>ANC of 1,500/mm<sup>3</sup> or less with severe chronic neutropenia of congenital, cyclic or idiopathic origin, or for use with peripheral blood progenitor cell (PBPC) transplantations</li> <li>Neutropenia due to acute leukemia (AML and ALL)</li> <li>WBC count less than 3.0 K/uL (3,000 cells/mm<sup>2</sup>) and is post-transplantation of the liver or kidney</li> </ul>		
<i>Please submit documentation.</i>		

### Granix Prior Authorization Form

You must answer ALL of the following questions		
1. Is the prescribed medication being used to prevent febrile neutropenia in a previously untreated adult or pediatric patient?	Y	N
2. Does the patient have a diagnosis of a non-myeloid malignancy and is the patient receiving chemotherapy and/or radiotherapy with an expected incidence of febrile neutropenia of 20% or greater?	Y	N
3. Is the patient at an increased risk for developing chemotherapy-induced infections due to any of the following reasons? <b>(Please Circle)</b>	Y	N
<ul style="list-style-type: none"> <li>Pre-existing neutropenia (ANC of 1,000/mm<sup>3</sup> or less)</li> <li>Extensive prior exposure to chemotherapy</li> <li>Previous exposure of pelvis or other areas of large amounts of bone marrow to radiation</li> <li>History of recurrent febrile neutropenia from chemotherapy</li> <li>Patient is 65 years of age or older</li> <li>Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS)</li> </ul>		
<i>Please submit documentation.</i>		
4. Does the patient have any of the following conditions? <b>(Please Circle)</b>	Y	N
<ul style="list-style-type: none"> <li>ANC of 1,000/mm<sup>3</sup> or less with BMT or myelodysplasia related neutropenia</li> <li>ANC of 500/mm<sup>3</sup> or less with HIV/AIDS</li> <li>ANC of 1,500/mm<sup>3</sup> or less with severe chronic neutropenia of congenital, cyclic or idiopathic origin, or for use with peripheral blood progenitor cell (PBPC) transplantations</li> <li>Neutropenia due to acute leukemia (AML and ALL)</li> <li>WBC count less than 3.0 K/uL (3,000 cells/mm<sup>2</sup>) and is post-transplantation of the liver or kidney</li> </ul>		
<i>Please submit documentation.</i>		

### Neulasta Prior Authorization Form

You must answer ALL of the following questions		
1. Does the patient weigh at least 45 kg or 99 lbs?	Y	N
2. Is the prescribed medication being used to prevent febrile neutropenia in a previously untreated adult or pediatric patient?	Y	N
3. Does the patient have a diagnosis of a non-myeloid malignancy and is the patient receiving chemotherapy and/or radiotherapy with an expected incidence of febrile neutropenia of 20% or greater?	Y	N



4. Is the patient at an increased risk for developing chemotherapy-induced infections due to any of the following reasons? **(Please Circle)**

- Pre-existing neutropenia (ANC of 1,000/mm<sup>3</sup> or less)
- Extensive prior exposure to chemotherapy
- Previous exposure of pelvis or other areas of large amounts of bone marrow to radiation
- History of recurrent febrile neutropenia from chemotherapy
- Patient is 65 years of age or older
- Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS)

Y	N
---	---

*Please submit documentation.*

**Please note, not all drugs/diagnoses are covered on all plans.**

Comments: \_\_\_\_\_

*Information given on this form is accurate as of this date.*

*Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically.*

\_\_\_\_\_  
**Prescriber or Authorized Signature**

\_\_\_\_\_  
**Date**

\_\_\_\_\_  
**Authorized Medical Staff – Name/Title**

**Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers appear on the Cover Page.**

**I understand that USDoctors use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).**



**Contact Information:**

Telephone: (855)251.9116

Fax: (248)593.9575

Please Note: Medical Necessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

**PRIOR AUTHORIZATION FORM:  
COVER PAGE**

MEMBER INFORMATION			
First Name		Last Name	
Plan			
Member ID		Date of Birth	
DRUG INFORMATION			
Drug Name			
Quantity		ICD-10	
Directions		Duration of Therapy	
Diagnosis			
PLEASE LIST ALTERNATIVE THERAPIES THAT HAVE BEEN ATTEMPTED AND ANY OTHER PERTINENT INFORMATION RELATED TO DRUG AND/OR DISEASE STATE. IF NOT PRESENT, WITHIN NORMAL LIMITS WILL BE USED FOR THE REVIEW.			
Medication/Failure Reason:			
IgE: _____			
ESR: _____ CRP: _____ # Joints: _____ %BSA: _____			
Height: _____ Weight: _____ BMI: _____			
HA1C: _____ Hemoglobin: _____ Hematocrit: _____ T-Score: _____			
Dialysis: _____ Long Term Care Facility: _____ Self Injecting: _____			
Stimulation test: _____ / _____ Growth velocity: _____ #Chemotherapy cycles/month: _____			
Mini-Mental Status Test: _____ Baseline Free testosterone/Total testosterone: _____ / _____			
HCV RNA viral load: _____ Viral Genotype: _____ ALT: _____			
PHYSICIAN INFORMATION			
Physician Signature		Date	
Physician Name		NPI #	
Phone Number		Fax Number	
Action Needed	Only mark Urgent when standard review time would seriously harm the member's life or health or ability to regain maximum function  <input type="checkbox"/> Urgent <input type="checkbox"/> For Review	Pharmacy Fax	
The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.			